Javascript was detected to be disabled. Javascript is required for some functions on this website.

The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization. It was established by scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience, to analyse health economic and treatment strategies (see Profile). Learn more about the institute's Purpose and Projects.

News

HTA Agencies Need Evidence-Informed Deliberative Processes

Epub ahead of print: Most recent publication on "HTA agencies need evidence-informed deliberative processes: Comment on "Use of evidence-informed deliberative processes by health technology assessment agencies around the globe" in the International Journal of Health Policy and Management (online available as of February 19, 2020).

Read more …

Availability, Accessibility and Delivery to Patients of Orphan Medicines approved by the EMA for Hereditary Metabolic Diseases

Now online available: Most recent research article by the MetabERN collaboration group on "Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network" in the Orphanet Journal of Rare Diseases (online available as of January 06, 2020).

Read more …

ISPOR 22nd Annual European Congress in Copenhagen / Denmark, November 05-08, 2019

Now online available: Poster Presentation on "Cancer-related HTA outcomes by European HTA agencies: a comparative analysis of G-BA, HAS and NICE" at the ISPOR 22nd Annual European Congress 2019 in Copenhagen / Denmark, November 05-08, 2019.

Read more …

Health Technology Assessment (HTA) and Economic Evaluation: Efficiency or Fairness first

Original Research Article by J. Richardson and M. Schlander (2019) on "Health Technology Assessment (HTA) and economic evaluation: Efficiency or fairness first" in the internationally well-known Journal of Market Access & Health Policy.

Read more …

Is NICE in England more "innovation-friendly" than G-BA in Germany?

Now online available: Most recent comparative analysis on "Is the National Institute for Health and Care Excellence (NICE) in England more ‘innovation-friendly’ than the Federal Joint Committee (G-BA) in Germany?" in the scientific journal Expert Review of Pharmacoeconomics & Outcomes Research (online available as of December 30, 2018).

Read more …